CN114099653A - Monocyte-loaded GPC3 protein antigen tumor vaccine composition and preparation method and application thereof - Google Patents

Monocyte-loaded GPC3 protein antigen tumor vaccine composition and preparation method and application thereof Download PDF

Info

Publication number
CN114099653A
CN114099653A CN202111254129.1A CN202111254129A CN114099653A CN 114099653 A CN114099653 A CN 114099653A CN 202111254129 A CN202111254129 A CN 202111254129A CN 114099653 A CN114099653 A CN 114099653A
Authority
CN
China
Prior art keywords
vaccine composition
monocyte
tumor vaccine
antigen
gpc3 protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111254129.1A
Other languages
Chinese (zh)
Inventor
孙忠杰
谢皇帆
李迎霞
苏红
宋婕
苏丹
李荣慧
王忠珍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Promise Future Technology Co ltd
Original Assignee
Beijing Promise Future Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Promise Future Technology Co ltd filed Critical Beijing Promise Future Technology Co ltd
Priority to CN202111254129.1A priority Critical patent/CN114099653A/en
Publication of CN114099653A publication Critical patent/CN114099653A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention discloses a tumor vaccine composition of monocyte-loaded GPC3 protein antigen, a preparation method and an application thereof, wherein the tumor vaccine composition consists of an antigen solution and monocytes, and is prepared by the following method: preparing antigen solution, separating peripheral blood or bone marrow to obtain mononuclear cells, mixing the obtained antigen solution and the obtained mononuclear cells, and making into tumor vaccine composition. The tumor vaccine composition with the monocyte loaded with the GPC3 protein antigen, the preparation method and the application of the tumor vaccine composition reduce the operation steps of conventional monocyte separation and differentiation to generate DC through simplified monocyte separation operation, thereby greatly reducing the vaccine preparation cost; the separated mononuclear cells are directly used for loading the GPC3 protein antigen, so that the remarkable anti-tumor effect is achieved, and the early-stage technical basis is provided for wider clinical tests.

Description

Monocyte-loaded GPC3 protein antigen tumor vaccine composition and preparation method and application thereof
Technical Field
The invention relates to the technical field of immunotherapy, in particular to a tumor vaccine composition with a monocyte loaded with a GPC3 protein antigen, and a preparation method and application thereof.
Background
Hepatocellular carcinoma (HCC) is the second largest malignancy in the world and is the leading cause of cancer death. The incidence and death rate of liver cancer in China account for more than 50% of the total number of people in China, and the death rate of liver cancer is the third in the world. While HCC treatment regimens tend to be multiplexed, combined, it is currently difficult to achieve further improvements in long-term survival in patients. The tumor vaccine is a gene containing tumor antigen or tumor antigen peptide. The tumor vaccine can induce specific cellular immunity and humoral immunity of an organism, further attack tumor cells, and prevent tumor growth, metastasis and recurrence, so that the tumor vaccine can be used as a means for treating liver cancer.
The development of the liver cancer vaccine depends on the specific antigen of the liver cancer cells, and GPC3 is an ideal target. GPC3 is specifically expressed on the surface of most liver cancer cells, but is rarely expressed in other tissues of adults. GPC3 belongs to the heparan sulfate proteoglycan family, and its structure includes a 60-70kD core protein and a carboxyl terminal modified with heparan sulfate side chain with glycosylphosphate, a phatidolinosol anchor (GPI) on the surface of cell membrane. GPC3 is a very suitable potential therapeutic target of liver cancer, and various GPC3 related vaccines (such as GPC3 epitope short peptide and GPC3 protein) are developed at present, but the effect is not ideal. The reason for this may be that the antigen-presenting efficiency of the body is too low.
Disclosure of Invention
Aiming at the technical problems in the related art, the invention provides a tumor vaccine composition with a monocyte loaded with a GPC3 protein antigen, and a preparation method and application thereof, which can overcome the defects in the prior art.
In order to achieve the technical purpose, the technical scheme of the invention is realized as follows:
a monocyte GPC3 protein antigen-loaded tumor vaccine composition, which consists of an antigen solution and monocytes, prepared by the following method:
s1 preparing an antigen solution;
s2 separating peripheral blood or bone marrow to obtain mononuclear cells;
s3 the antigen solution obtained in S1 was mixed with the monocyte obtained in S2 to prepare a tumor vaccine composition.
Preferably, the antigen solution is a solution of a characteristic substance that induces an immune response to Th1 in the body.
Preferably, the characteristic substance is GPC3 protein.
According to another aspect of the present invention, there is provided a method for preparing a monocyte-loaded GPC3 protein antigen-containing tumor vaccine composition, the method comprising the steps of:
s1 preparing an antigen solution;
s2 separating peripheral blood or bone marrow to obtain mononuclear cells;
s3 the antigen solution obtained in S1 was mixed with the monocyte obtained in S2 to prepare a tumor vaccine composition.
Preferably, the antigen solution in S1 is a GPC3 protein solution prepared from GPC3 protein and PBS, and the concentration of the GPC3 protein solution is 1 mg/mL.
Preferably, the monocytes are taken from peripheral blood or bone marrow.
Preferably, the mononuclear cells are prepared by adopting a lymph separation liquid Ficoll density gradient centrifugation method.
The invention also provides application of the tumor vaccine composition in preparation of a product for treating liver cancer.
Preferably, the tumor vaccine composition is administered intravenously.
The invention has the beneficial effects that: the tumor vaccine composition with the monocyte loaded with the GPC3 protein antigen, the preparation method and the application of the tumor vaccine composition reduce the operation steps of conventional monocyte separation and differentiation to generate DC through simplified monocyte separation operation, thereby greatly reducing the vaccine preparation cost; the separated mononuclear cells are directly used for loading the GPC3 protein antigen, so that the remarkable anti-tumor effect is achieved, and the early-stage technical basis is provided for wider clinical tests.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings needed in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings without creative efforts.
FIG. 1 is a graph showing the measurement results of the phagocytosis of GPC3 protein by mouse bone marrow-derived mononuclear cells according to an embodiment of the present invention, including a flow chart and a bar graph of statistical data;
FIG. 2 is the result of detecting peripheral blood GPC3 specific T at day 14 after monocyte GPC3 protein tumor vaccine immunization of A2 receptor mice, including flow representative graph and statistical data bar chart;
FIG. 3 is a graph showing the statistical data of the detection results of peripheral blood GPC3 specific antibodies on day 14 after immunization of A2 recipient mice with monocyte GPC3 protein tumor vaccine;
FIG. 4 shows the curves of the growth of tumors in mice bearing tumors of the QGY7703 cell line by GPC3 monocyte vaccine (preventive model), injected on days-21, -14 and-7, and inoculated with tumor cells on day 0;
FIG. 5 shows the curves of the growth of tumors in mice bearing tumors of the QGY7703 cell line by GPC3 monocyte vaccine (therapeutic model), inoculated with tumor cells on day 0, and injected with vaccine on days 7 and 14.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments that can be derived by one of ordinary skill in the art from the embodiments given herein are intended to be within the scope of the present invention.
Monocytes and their derivatives can transfer antigen to cdcs in vivo. Studies have shown that CD8+ cdcs resident in lymphoid organs, CD8+ cdcs dedicated to cross-priming naive CD8+ T cells to induce CTL responses, can activate memory CD8+ T cells by obtaining antigen from other cells in the body by phagocytosis or trogocytosis. Therefore, the novel antigen vaccine of the monocyte-loaded GPC3 protein is prepared by assuming that the monocyte can deliver the antigen to endogenous cDC and developing a novel effective antigen cell vaccine platform by using the method of loading the antigen by the monocyte.
The invention provides a tumor vaccine composition of a monocyte-loaded GPC3 protein antigen, which consists of an antigen solution and monocytes, and is prepared by the following method:
s1 preparing an antigen solution;
s2 separating peripheral blood or bone marrow to obtain mononuclear cells;
s3 the antigen solution obtained in S1 was mixed with the monocyte obtained in S2 to prepare a tumor vaccine composition.
Wherein, the antigen solution is a solution of a characteristic substance for inducing the body Th1 immune response.
In some embodiments, the characteristic substance is GPC3 protein.
According to another aspect of the present invention, there is provided a method for preparing a monocyte-loaded GPC3 protein antigen-containing tumor vaccine composition, the method comprising the steps of:
s1 preparing an antigen solution;
s2 separating peripheral blood or bone marrow to obtain mononuclear cells;
s3 the antigen solution obtained in S1 was mixed with the monocyte obtained in S2 to prepare a tumor vaccine composition.
Wherein, the antigen solution in S1 is GPC3 protein solution prepared from GPC3 protein and PBS, and the concentration is 1 mg/mL.
In some embodiments, the mononuclear cells are obtained from peripheral blood or bone marrow and prepared using a lymph separator Ficoll density gradient centrifugation method.
The invention also provides application of the tumor vaccine composition in preparation of a product for treating liver cancer, wherein the tumor vaccine composition is injected intravenously.
The raw material manufacturers in the following examples are shown in table 1:
TABLE 1 raw material table
Figure BDA0003323458110000041
Example 1
The separation of the mononuclear cells comprises the following steps:
(1) the mice were sacrificed by cervical dislocation, 2 femurs were taken, both ends of the femurs were cut off, and appropriate amount of PBS was sucked into the femurs by a syringe to repeatedly wash the bone cavity of the femurs to obtain bone marrow eluate, which was collected into a PE centrifuge tube after being filtered by a 40 μ M mesh.
(2) Centrifuging at 500g for 5min at 300-; adding 4mL of PBS to resuspend the bone marrow cells; at the same time, 3mL of Ficoll lymph separation medium was added to another PE centrifuge tube. The bone marrow cell suspension was gently added to the PE centrifuge tube containing the Ficoll lymph separation medium, taking care not to disrupt the interface between the cell suspension and the lymph separation medium.
(3) Centrifuging a PE centrifuge tube for 30min at 400g, wherein the centrifuge tube is divided into four layers from top to bottom due to different densities: the first layer is a plasma layer, the second layer is an annular milky white monocyte layer, the third layer is a transparent separation liquid layer, and the fourth layer is a red blood cell layer. Carefully sucking the second annular milky white monocyte layer into another 50ml centrifuge tube by using a pipette, supplementing PBS, and centrifuging for 5-10 min at 400 g.
(4) Discarding the supernatant, adding PBS for resuspension, centrifuging for 5-10 min at 400g, discarding the supernatant to obtain monocyte mass, resuspending in a proper amount of RPMI 1640 medium containing 10% inactivated FBS, and counting.
Example 2
Loading the monocyte obtained by the method with a GPC3 protein antigen, and comprising the following steps:
(1) GPC3 protein was dissolved in RPMI 1640 medium containing 10% inactivated FBS at a concentration of 1 mg/mL.
(2) Adding monocytes into the GPC3 protein solution to ensure that the density of monocytes is consistent, all 2 × 107Individual cells/mL.
(3) And (3) putting the cell suspension obtained in the step (2) into a constant-temperature incubator, incubating for 2 hours at 37 ℃ and 5% CO2, and shaking for 1 time every half hour.
(4) And after the incubation is finished, centrifuging the cell suspension for 5-10 min at 400g, removing the supernatant, adding a proper amount of PBS (phosphate buffer solution) for heavy suspension, centrifuging for 5-10 min at 400g, and removing the supernatant to obtain the monocyte mass loaded with the GPC3 protein antigen.
(5) The above-mentioned monocytes loaded with the GPC3 protein antigen were resuspended in RPMI 1640 medium to a final cell concentration of 5X 107Each cell/mL, the mixed solution is the liver cancer vaccine composition. GPC3 protein loading was detected with PE-his-tag flow antibody. The results of measuring the phagocytosis efficiency of GPC3 by monocytes are shown in FIG. 1.
Example 3
The antigen vaccine composition obtained above is used for immunizing a mouse model, and comprises the following steps:
(1) the suspension of monocytes loaded with the GPC3 protein was injected into A2 mice in a volume of 200. mu.L from the tail vein, and each mouse was inoculated with 1X 10 cells7Control mice were injected with an equal volume of PBS. The inoculation was continued 3 times, 1 time every 7 days.
(2) The growth of the tumor of the mice was continuously followed and measured starting on day 7 after the tumor inoculation, and the serum production and the production of specific T cells were analyzed on day 14 after the first vaccination, the results of the detection of peripheral blood GPC3 specific T on day 14 after the monocyte GPC3 protein tumor vaccine immunized A2 recipient mice are shown in FIG. 2, and the results of the detection of peripheral blood GPC3 specific antibody on day 14 after the monocyte GPC3 protein tumor vaccine immunized A2 recipient mice are shown in FIG. 3.
(3) Preventive models: each mouse was inoculated with tumor cells 14 days from the first vaccination. The tumor cell inoculation amount of each mouse is 1 × 106The inoculation mode is subcutaneous injection. The mouse tumor growth curve is shown in fig. 4.
(4) Therapeutic models: the tumor cell inoculation amount of each mouse is 1 × 106The inoculation mode is subcutaneous injection. GPC3 protein monocyte vaccines were administered on days 7 and 14 after tumor inoculation, respectively. The mouse tumor growth curve is shown in fig. 5.
The tumor vaccine composition with the monocyte-loaded GPC3 protein antigen provided by the invention is a multifunctional personalized antigen vaccine composition, has a high-efficiency resistance effect of overcoming antigen heterogeneity and strong specificity, and can be used for preparing liver cancer treatment products.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.

Claims (9)

1. A monocyte GPC3 protein antigen-loaded tumor vaccine composition, which consists of an antigen solution and monocytes, and is prepared by the following method:
s1 preparing an antigen solution;
s2 separating peripheral blood or bone marrow to obtain mononuclear cells;
s3 the antigen solution obtained in S1 was mixed with the monocyte obtained in S2 to prepare a tumor vaccine composition.
2. The tumor vaccine composition according to claim 1, wherein the antigen solution is a solution of a characteristic substance that induces an immune response of Th1 in a body.
3. The tumor vaccine composition according to claim 2, wherein the characteristic substance is GPC3 protein.
4. A preparation method of a tumor vaccine composition with a monocyte loaded with GPC3 protein antigen is characterized by comprising the following steps:
s1 preparing an antigen solution;
s2 separating peripheral blood or bone marrow to obtain mononuclear cells;
s3 the antigen solution obtained in S1 was mixed with the monocyte obtained in S2 to prepare a tumor vaccine composition.
5. The method of claim 4, wherein the antigen solution of S1 is GPC3 protein solution prepared from GPC3 protein and PBS, and the concentration of the GPC3 protein solution is 1 mg/mL.
6. The method of claim 4, wherein the monocytes are obtained from peripheral blood or bone marrow.
7. The method of claim 6, wherein the mononuclear cells are prepared by Ficoll density gradient centrifugation of a lymph separation medium.
8. Use of the tumor vaccine composition of claim 1 in the preparation of a product for treating liver cancer.
9. The use according to claim 8, wherein the tumor vaccine composition is administered intravenously.
CN202111254129.1A 2021-10-27 2021-10-27 Monocyte-loaded GPC3 protein antigen tumor vaccine composition and preparation method and application thereof Pending CN114099653A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111254129.1A CN114099653A (en) 2021-10-27 2021-10-27 Monocyte-loaded GPC3 protein antigen tumor vaccine composition and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111254129.1A CN114099653A (en) 2021-10-27 2021-10-27 Monocyte-loaded GPC3 protein antigen tumor vaccine composition and preparation method and application thereof

Publications (1)

Publication Number Publication Date
CN114099653A true CN114099653A (en) 2022-03-01

Family

ID=80376956

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111254129.1A Pending CN114099653A (en) 2021-10-27 2021-10-27 Monocyte-loaded GPC3 protein antigen tumor vaccine composition and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN114099653A (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090285851A1 (en) * 2007-11-19 2009-11-19 Seoul National University Industry Foundation Vaccine comprising monocyte or immature myeloid cells (imc) which were loaded with the ligand of natural killer t cell and antigen
CN104524560A (en) * 2015-01-07 2015-04-22 天津市第一中心医院 Dendritic cell tumor vaccine and preparation method and application thereof
WO2017177910A1 (en) * 2016-04-11 2017-10-19 中国科学院上海巴斯德研究所 Novel immune strategy and immune composition for enhancing anti-tumour immune response
CN107583042A (en) * 2017-08-14 2018-01-16 北京启辰生生物科技有限公司 A kind of general hepatic carcinoma antigen composition and its production and use
CN110478474A (en) * 2019-08-21 2019-11-22 启辰生生物科技(珠海)有限公司 Immunomodulator, vaccine, cell and application
US20210205428A1 (en) * 2019-12-03 2021-07-08 Neuvogen, Inc. Tumor cell vaccines

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090285851A1 (en) * 2007-11-19 2009-11-19 Seoul National University Industry Foundation Vaccine comprising monocyte or immature myeloid cells (imc) which were loaded with the ligand of natural killer t cell and antigen
CN104524560A (en) * 2015-01-07 2015-04-22 天津市第一中心医院 Dendritic cell tumor vaccine and preparation method and application thereof
WO2017177910A1 (en) * 2016-04-11 2017-10-19 中国科学院上海巴斯德研究所 Novel immune strategy and immune composition for enhancing anti-tumour immune response
CN107583042A (en) * 2017-08-14 2018-01-16 北京启辰生生物科技有限公司 A kind of general hepatic carcinoma antigen composition and its production and use
CN110478474A (en) * 2019-08-21 2019-11-22 启辰生生物科技(珠海)有限公司 Immunomodulator, vaccine, cell and application
US20210205428A1 (en) * 2019-12-03 2021-07-08 Neuvogen, Inc. Tumor cell vaccines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUANG,M.N.等: "Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses", J.CLIN.INVEST., vol. 130, no. 2, pages 775 *
TADA,F.等: "Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma", INT.J.ONCOL., vol. 41, no. 5, pages 1602 *

Similar Documents

Publication Publication Date Title
CN111481662A (en) Individual specific therapeutic vaccine for tumor and preparation method thereof
CN112877288A (en) NK cell culture system and application
CN103599528A (en) Method for preparing human dendritic cell vaccine
Liu et al. Synthetic MUC1 breast cancer vaccine containing a Toll‑like receptor 7 agonist exerts antitumor effects
CN104262459B (en) Acute monocytic leukemia-associated antigen MLAA-34 epitope polypeptide, and vaccine and pharmaceutical application of acute monocytic leukemia-associated antigen MLAA-34 epitope polypeptide
CN105031641A (en) DC-based HCV epitope vaccine and preparation method thereof
CN102596234B (en) Dendritic cell vaccine for the tumor expressing asparaginyl--B-hydroxylase
CN115957306A (en) Application of Caerin1.1/1.9 combined anti-CD47 antibody in preparation of drugs for treating melanoma
WO2014026457A1 (en) Industrial preparation of natural killer cells (nks) and injection using human allogeneic karyocytes
CN107365742B (en) CD4+T cell-derived exosomes and use thereof
CN104357393B (en) A kind of isolated culture method of chicken intestinal epithelium gamma delta T cells
CN114099653A (en) Monocyte-loaded GPC3 protein antigen tumor vaccine composition and preparation method and application thereof
US9089593B2 (en) Dendritic cell tumor injection (DCTI) therapy
WO2023005486A1 (en) Ebv composite antigen, dendritic cell vaccine and use thereof
CN105219727A (en) A kind of test kit for activating colorectal cancer specific immune response
CN110585427B (en) Composition for improving immunity of organism and application of composition in resisting adult T cell leukemia or nasopharyngeal carcinoma
CN105219728A (en) A kind of for activating the immunoreactive test kit of Breast Cancer-Specific
CN112010960A (en) Tumor antigen complex in-vitro sensitized DC and T cell obtained tumor specific killer cell CTL and preparation method thereof
CN114028552A (en) Monocyte-loaded LMP1 protein vaccine composition and preparation method and application thereof
CN105602900A (en) Culturing method of adenovirus gene-modifying tumor specificity cytotoxic T lymphocyte
CN114099654A (en) Vaccine composition of monocyte-loaded liver cancer cell lysate and preparation method and application thereof
CN111073853A (en) Preparation method of TIL cell, kit and reagent set
CN105219715A (en) A kind of test kit for activating esophageal carcinoma specific immune response
CN104761636B (en) A kind of restricted eEF2 epitope polypeptides of HLA-A33 and its application
CN105219723A (en) A kind of test kit for activating cancer of the stomach specific immune response

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination